Dr Connolly highlights the cautious patient selection and the significance of reducing hematoma expansion for improved outcomes in cases of intracerebral hemorrhage (ICH) associated with the use of a reversal agent for factor Xa inhibitors.
Stuart J. Connolly, MD, FRCPC
Advertisement
Articles by Stuart J. Connolly, MD, FRCPC
A medical expert discusses the findings of a randomized trial investigating the use of andexanet alfa versus usual care in patients with acute intracerebral hemorrhage (ICH) and recent direct oral anticoagulant (DOAC) use.
Stuart J Connolly, MD, FRCPC, discusses updated strategies for managing intracerebral hemorrhage, emphasizing the significance of timely diagnosis to improve hemostatic efficacy.
Advertisement
Latest Updated Articles
DOAC Usage and Rapid Access to Reversal AgentsPublished: November 20th 2023 | Updated:
- Key Takeaways From ANNEXA-I Study
Published: December 4th 2023 | Updated:
- ANNEXA-I Study Overview
Published: November 27th 2023 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
2
NLRP3 Inhibitor VTX3232 Well Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
3
Episode 152: Building Safer, Smarter, and More Personalized Epilepsy Care
4
OnabotulinumtoxinA Meets Primary End Point in Phase 2 ELATE Trial for Upper Limb Essential Tremor
5
